InvestSMART

Avecho Biotechnology Limited (ASX: AVE) - Announcements

- Current share price for AVE : $0.019

ASX company news and announcements for Avecho Biotechnology Limited (AVE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Avecho Biotechnology Limited (AVE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Avecho Biotechnology Limited (AVE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Avecho Biotechnology Limited (AVE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$73 Notice of Annual General Meeting/Proxy Form 24 Apr 2026 9:06AM $0.010 $0.019 risen by 90%
$73 Avecho to present at NWR Virtual Healthcare Conference 24 Mar 2026 9:19AM $0.008 $0.019 risen by 137.50%
$73 Avecho completes recruitment for Phase III interim analysis 2 Mar 2026 9:23AM $0.009 $0.019 risen by 111.11%
$73 Appendix 4G and Corporate Governance Statement 27 Feb 2026 4:05PM $0.009 $0.019 risen by 111.11%
$73 Annual Report 31 December 2025 27 Feb 2026 4:04PM $0.009 $0.019 risen by 111.11%
$73 Avecho CEO to Present at Euroz Hartleys Healthcare Forum 5 Feb 2026 9:08AM $0.009 $0.019 risen by 111.11%
$73 December 2025 Quarterly Activities Report & Appendix 4C 29 Jan 2026 1:54PM $0.010 $0.019 risen by 100%
$73 Phase III CBD Clinical Trial Recruitment Update 18 Dec 2025 10:32AM $0.010 $0.019 risen by 90%
$73 AVE Secures US & EU Patent Allowances for CBD Soft-Gel 3 Dec 2025 11:32AM $0.008 $0.019 risen by 137.50%
$73 Application for quotation of securities - AVE 3 Nov 2025 11:00AM $0.006 $0.019 risen by 216.67%
$73 Application for quotation of securities - AVE 3 Nov 2025 9:57AM $0.006 $0.019 risen by 216.67%
$73 Section 708A Cleansing Statement 3 Nov 2025 9:55AM $0.006 $0.019 risen by 216.67%
$73 September 2025 Quarterly Activities Report & Appendix 4C 31 Oct 2025 12:55PM $0.006 $0.019 risen by 216.67%
$73 Proposed issue of securities - AVE 23 Oct 2025 8:56AM $0.007 $0.019 risen by 192.31%
$73 Proposed issue of securities - AVE 23 Oct 2025 8:54AM $0.007 $0.019 risen by 192.31%
$73 Avecho raises $2.5m via placement 23 Oct 2025 8:54AM $0.007 $0.019 risen by 192.31%
$73 Presentation to Ausbiotech Invest 2025 21 Oct 2025 8:29AM $0.006 $0.019 risen by 216.67%
$73 Update - Notification regarding unquoted securities - AVE 1 Oct 2025 8:52AM $0.006 $0.019 risen by 216.67%
$73 Appendix 4D and Half-year Financial Report 28 Aug 2025 3:16PM $0.006 $0.019 risen by 216.67%
$73 June 2025 Quarterly Activities Report & Appendix 4C 30 Jul 2025 8:44AM $0.005 $0.019 risen by 280%
$73 Phase III Insomnia Trial Recruitment Update 29 Jul 2025 9:08AM $0.005 $0.019 risen by 322.22%
$73 Change in Substantial Holding 25 Jun 2025 9:25AM $0.004 $0.019 risen by 375%
$73 Receipt of R&D Tax Incentive 28 May 2025 11:24AM $0.005 $0.019 risen by 280%
$73 Change of Director's Interest Notice x4 27 May 2025 3:02PM $0.005 $0.019 risen by 280%
$73 Notification regarding unquoted securities - AVE 27 May 2025 2:53PM $0.005 $0.019 risen by 280%

26 - 50 of 312 results

Page 2 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.